PD-1 Antibody: BMS and Ono Signed Agreement with Merck

U.S. based one of the leading Pharmaceutical company Bristol-Myers Squibb ( BMS )and Japan based Ono Pharmaceutical Company, Ltd. recently declared that the organizations have agreed on an international patent license agreement with Merck & Co. Inc. to negotiate all patent-violation lawsuits relevant to Merck’s PD-1 antibody Keytruda (pembrolizumab). According to BMS, the deal will lead to the dismissal with prejudice of all patent lawsuits in between the organizations…

Merck’s rVSV-EBOV Vaccine Showed Promising Outcomes in Protecting against Ebola

According to recent clinical trial outcomes, Merck’s rVSV-EBOV vaccine showed to be highly effective in protecting against human infection with Ebola. This trial enrolled 5,837 subjects who obtained the rVSV-EBOV vaccine in Guinea in 2015, no Ebola cases were noted 10 days or more after vaccination, signaling 100 % protection.

Over 11,300 individuals died in West Africa’s 2013-2016 outbreak of the virus,…

NPPA Caps Prices of another Eighteen Formulations

The Pharmaceutical pricing agency of India, National Pharmaceutical Pricing Authority (NPPA) has capped the prices of a further 18 products, which includes drugs sold by Cipla and Merck. Drugs to deal with diabetes, hypertension and pneumonia are impacted by the extension of the price-capping policy.

NPPA has included more drugs packs to the list of price-capped drugs on various occasions since the…

Novo Nordisk Takes the Top Position in 2014 Diabetes Sales

It is good time for diabetes drug manufacturers, top 10 pharmaceutical companies producing diabetes medicines generated around $62 billion in sales in 2014 which means it increased by 5.1% compared to 2013.

This is based on a report from the data analytics company Global Data which stated that Novo Nordisk is in the top position with $11.3 billion diabetes sales last year followed by Sanofi and Merck with sales of…

Merck joins forces with Serum Institute to create child vaccine

Earlier on Wednesday, drug maker Merck & Co. announced that it has decided to join forces with Serum Institute of India Ltd. in an effort to develop a child Pneumococcal vaccine for use in emerging and developing countries. Pneumococcal disease occurs due to infection by a bacteria resulting in sickness including pneumonia and meningitis. Although the terms of agreement were not…